- Norisoboldine
-
- $48.00
-
2026-08-26
- CAS:23599-69-1
- Purity: 99.70%
- Supply Ability: 10g
- norisoboldine
-
-
2026-06-30
- CAS:23599-69-1
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kg
- norisoboldine
-
- $1.00
-
2019-07-14
- CAS:23599-69-1
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 25kg
|
| | norisoboldine Basic information |
| Product Name: | norisoboldine | | Synonyms: | norisoboldine;(+)-Laurelliptine;(+)-N-Norisoboldine;(6aS)-5,6,6a,7-Tetrahydro-2,10-dimethoxy-4H-dibenzo[de,g]quinoline-1,9-diol;(S)-(+)-Laurelliptine;Norisoboldine, 98%, from Lindera aggregata (Sims) Kosterm.;4H-Dibenzo[de,g]quinoline-1,9-diol, 5,6,6a,7-tetrahydro-2,10-dimethoxy-, (6aS)-;(+)-Norisoboldine | | CAS: | 23599-69-1 | | MF: | C18H19NO4 | | MW: | 313.35 | | EINECS: | | | Product Categories: | chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract | | Mol File: | 23599-69-1.mol |  |
| | norisoboldine Chemical Properties |
| Melting point | 89-191℃ | | Boiling point | 553.0±50.0 °C(Predicted) | | density | 1.313 | | solubility | ≥ 31.3mg/mL in DMSO | | pka | 9.58±0.20(Predicted) | | form | Powder | | color | Brown to khaki | | InChI | InChI=1S/C18H19NO4/c1-22-14-8-11-10(6-13(14)20)5-12-16-9(3-4-19-12)7-15(23-2)18(21)17(11)16/h6-8,12,19-21H,3-5H2,1-2H3/t12-/m0/s1 | | InChIKey | HORZNQYQXBFWNZ-LBPRGKRZSA-N | | SMILES | N1[C@]2([H])C3=C(C(O)=C(OC)C=C3CC1)C1=CC(OC)=C(O)C=C1C2 |
| Safety Statements | 24/25 | | HS Code | 29339900 |
| | norisoboldine Usage And Synthesis |
| Chemical Properties | Brown crystalline powder, soluble in methanol, derived from Linderae odorata. | | Uses | (+)-Norisoboldine is an anti-arthritis alkaloid isolated from radix linderae which has been shown to attenuate osteoclast differentiation and inflammatory bone erosion in aryl hydrocarbon receptor-dependant manner. | | in vivo | Norisoboldine (10~40 mg/kg; p.o.; 20 days) significantly reduces the severity of joint swelling and erythema during the course of the experiment[1].
Norisoboldine (40 mg/kg; i.g.; 10 days) induces enhancement of CYP1A1 expression and suppresses expressions of Glut1 and HK2 in colons[2]. | Animal Model: | Male ICR mice (18–22 g) | | Dosage: | 10~40 mg/kg | | Administration: | P.o. | | Result: | Significantly reduced the severity of joint swelling and erythema during the course of the experiment.
|
| Animal Model: | Female C57BL/6 mice (18–22 g) | | Dosage: | 40 mg/kg | | Administration: | I.g. | | Result: | Induced enhancement of CYP1A1 expression and suppressed expressions of Glut1 and HK2 in colons.
|
|
| | norisoboldine Preparation Products And Raw materials |
|